Read by QxMD icon Read

Future Cardiology

Jesse X Yang, Robert W Yeh
Drug-eluting stents revolutionized the treatment of coronary artery disease with vastly improved outcomes compared with bare metal stents. As stent technology has evolved, a wide variety of antiproliferative drugs have been developed to prevent stent restenosis and stent thrombosis. The Resolute stent system (Medtronic, CA, USA) elutes zotarolimus from a multipolymer blend to prevent early and late stent-related complications. The Resolute stents have evolved from the initial Resolute stent, to the Resolute Integrity™ and most recently, the Resolute Onyx™...
February 16, 2018: Future Cardiology
Rui Shi, Mark Norman, Zhong Chen, Tom Wong
Atrial fibrillation (AF) is the most common clinical arrhythmia encountered. Catheter ablation has become the first-line therapy for symptomatic drug-refractory paroxysmal and persistent AF. Although pulmonary vein electrical isolation is still the cornerstone of the ablation strategy, the clinical outcome particularly in treating persistent AF is suboptimal. Significant efforts have been applied with live global chamber mapping of AF aimed to identify patient-specific drivers and/or maintainers located outside of the pulmonary veins to further improve the outcome of catheter ablation...
February 14, 2018: Future Cardiology
Azadeh Shohoudi, David A Stephens, Paul Khairy
Escalating costs of cardiovascular trials are limiting medical innovations, prompting the development of more efficient and flexible study designs. The Bayesian paradigm offers a framework conducive to adaptive trial methodologies and is well suited for the study of small populations. Bayesian adaptive trials provide a statistical structure for combining prior information with accumulating data to compute probabilities of unknown quantities of interest. Adaptive design features are useful in modifying randomization schemes, adjusting sample sizes and providing continuous surveillance to guide decisions on dropping study arms or premature trial interruption...
February 6, 2018: Future Cardiology
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Coronary lesions at bifurcation sites are frequent and still remain a challenging subset for the interventional cardiologist. Although in the last years the provisional stenting technique has shown more consistent results, coronary bifurcation interventions still share a worse procedural success rate and increased rates of mid- and long-term cardiac events. Most of the dedicated devices proposed in the last few years have failed to show improved results when compared with standard devices. The broader use of imaging techniques, such as intravascular ultrasound and optical coherence tomography, lead to a better understanding of the real anatomy of bifurcations and has shown to be a great tool for percutaneous coronary intervention optimization...
January 26, 2018: Future Cardiology
Atul Gupta
Atul Gupta, MD speaks to Adam Price-Evans, Managing Commissioning Editor of Future Cardiology. Atul Gupta is the Global Chief Medical Officer for the business group Image Guided Therapy at Philips, providing medical guidance to Philips' clinical vision and strategy. As a practicing interventional and diagnostic radiologist, he also serves as a key external clinical voice for Image Guided Therapy. His key responsibilities include supporting innovation and product development in cardiology, peripheral vascular, surgical, oncology interventions, clinical education, office-based labs, medical affairs and new business development and ventures...
January 23, 2018: Future Cardiology
Carol Chen-Scarabelli, William G Hundley, Tiziano M Scarabelli
No abstract text is available yet for this article.
January 22, 2018: Future Cardiology
Bruno Bordoni, Fabiola Marelli, Bruno Morabito, Beatrice Sacconi
No abstract text is available yet for this article.
January 22, 2018: Future Cardiology
Diana Glovaci, Ali Naqvi, Katherine Yu, Pranav Patel, Mayil Krishnam
AIM: Postmyocardial infarction ventricular septal defect (VSD) is a rare complication that can lead to rapid hemodynamic patient decompensation. The type of VSD repair relies on several factors including: size, location, timing and surgical expertise. CASE: A 63-year-old man with a ST-elevation myocardial infarction underwent percutaneous coronary intervention of the right coronary artery. A holosystolic murmur was notable postcatheterization, and transthoracic echocardiogram confirmed a VSD...
January 22, 2018: Future Cardiology
Juan Tang, Kathy O Lui, Bin Zhou
No abstract text is available yet for this article.
January 16, 2018: Future Cardiology
Alexander N Kharlamov, Ilya V Zubarev, Ekaterina V Shishkina, Vladimir Ya Shur
No abstract text is available yet for this article.
January 16, 2018: Future Cardiology
Gulten Tacoy
No abstract text is available yet for this article.
January 16, 2018: Future Cardiology
Robert J Henning
One out of every two men and one out of every three women greater than the age of 40 will experience an acute myocardial infarction (AMI) at some time during their lifetime. As more patients survive their AMIs, the incidence of congestive heart failure (CHF) is increasing. 6 million people in the USA have ischemic cardiomyopathies and CHF. The search for new and innovative treatments for patients with AMI and CHF has led to investigations and use of human embryonic stem cells, cardiac stem/progenitor cells, bone marrow-derived mononuclear cells and mesenchymal stem cells for treatment of these heart conditions...
March 2018: Future Cardiology
Nandhinee Radha Shanmugam, Sriram Muthukumar, Ambalika Sanjeev Tanak, Shalini Prasad
AIM: Development of a label-free multiplexed point-of-care diagnostic device for a panel of cardiac biomarkers - cardiac troponin-T (cTnT), troponin-I (cTnI) and B-type natriuretic peptide (BNP). METHODS: A nonfaradaic electrochemical immunoassay designed with anisotropic high surface area ZnO nanostructures grown using low-temperature hydrothermal methods was selectively immobilized with capture antibodies. Multiplexed detection in human serum using ZnO nanostructures based on complementary electrochemical measurement techniques - electrochemical impedance spectroscopy and Mott-Schottky...
March 2018: Future Cardiology
Panagiota Anna Chousou, Peter J Pugh
A substantial proportion of patients who undergo cardiac device implantation receive oral anticoagulation to prevent thromboembolism or antiplatelets to prevent thrombotic events. Anticoagulation and antiplatelets increase the risk of hemorrhagic complications, while discontinuation may increase thromboembolic risk and thrombotic events. With the introduction of non-vitamin K antagonist oral anticoagulant agents and the newer antiplatelet agents such as prasugrel or ticagrelor, the perioperative management of patients has become more challenging...
March 2018: Future Cardiology
Anna Jacobs, Rajesh Kabra, Pranab Das, Carrie S Oliphant
Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available...
January 2018: Future Cardiology
Fatima Donia Mili, Tenecia Allen, Paula Weinstein Wadell, W Craig Hooper, Christine De Staercke, Christopher J Bean, Cathy Lally, Harland Austin, Nanette K Wenger
AIM: The study objectives were to investigate the association between selected CYP2C9 and VKORC1 single nucleotide polymorphisms with serious bleeding or thrombotic risk, and to estimate mean daily maintenance dose of warfarin and international normalized ratio measurements among Blacks receiving warfarin anticoagulation. METHODS: We conducted a retrospective cohort study among 230 Black adults receiving warfarin for a minimum of three consecutive months with a confirmed date of first dosage...
January 2018: Future Cardiology
Rizwan Rehman, Mood Che Marhisham, Mazeni Alwi
Patent ductus arteriosus (PDA) stenting has gained acceptance for palliation in cyanotic congenital heart disease. The PDA in tetralogy of Fallot with pulmonary atresia (ToF-PA) arises, in the left aortic arch, from underneath the arch and connects to the proximal left pulmonary artery, often resulting in stenosis. The PDA is usually elongated and tortuous, making stent implantation challenging. Shorter duration of palliation, aggravation of branch pulmonary artery stenosis resulting in poor growth and difficulty at surgery makes ductal stenting controversial...
January 2018: Future Cardiology
Amina Valjevac, Damir Rebic, Aida Hamzic-Mehmedbasic, Emir Sokolovic, Dzan Horozic, Nedim Vanis, Almira Hadzovic-Dzuvo
AIM: To assess the utility of gamma-glutamyl transferase (GGT) and C-reactive protein (CRP) in predicting troponin elevation in patients with acute coronary syndrome. PATIENTS: The total of 119 patients were divided into troponin-positive (n = 61) and troponin-negative (n = 58) patients. RESULTS: CRP cut-off value ≥13.4 mg/l had the sensitivity of 68.1% and specificity of 62.5%, while the GGT cut-off value ≥61.5 IU/l had the sensitivity of 66...
January 2018: Future Cardiology
Grant M Tinsley, Benjamin D Horne
Intermittent fasting has produced a variety of beneficial health effects in animal models, although high-quality research in humans has been limited. This special report examines current evidences for intermittent fasting in humans, discusses issues that require further examination, and recommends new research that can improve the knowledge base in this emerging research area. While potentially useful for health improvement, intermittent fasting requires further study prior to widespread implementation for health purposes...
January 2018: Future Cardiology
Hideki Koike, Tadashi Fujino, Makiko Koike, Shintaro Yao, Katsuya Akitsu, Masaya Shinohara, Hitomi Yuzawa, Takeya Suzuki, Takanori Ikeda
AIM: The aim of this study was to examine cancer and bleeding in atrial fibrillation patients administered with dabigatran. MATERIALS & METHODS: This study enrolled 509 consecutive nonvalvular atrial fibrillation patients who received dabigatran. The mean administration period was 14.8 ± 15.7 months. We investigated the prevalence and new development of cancers. Further, the relation between cancer and adverse events was evaluated. RESULTS: In the 509 patients, major bleeding occurred in 2...
January 2018: Future Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"